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Abstract
Purpose: We propose and simulate a model-based methodology to incorporate
heterogeneous treatment benefit of proton therapy (PrT) versus photon therapy into
randomized trial designs. We use radiation-induced pneumonitis (RP) as an exemplar.
The aim is to obtain an unbiased estimate of how predicted difference in normal tissue
complications probability (DNTCP) converts into clinical outcome on the patient level.
Materials and Methods: DNTCP data from in silico treatment plans for photon therapy
and PrT for patients with locally advanced lung cancer as well as randomly sampled
clinical risk factors were included in simulations of trial outcomes. The model used at
point of analysis of the trials was an iQUANTEC model. Trial outcomes were examined
with Cox proportional hazards models, both in case of a correctly specified model and in
a scenario where there is discrepancy between the dose metric used for DNTCP and the
dose metric associated with the ‘‘true’’ clinical outcome, that is, when the model is
misspecified. We investigated how outcomes from such a randomized trial may feed into
a model-based estimate of the patient-level benefit from PrT, by creating patient-specific
predicted benefit probability distributions.
Results: Simulated trials showed benefit in accordance with that expected when the
NTCP model was equal to the model for simulating outcome. When the model was
misspecified, the benefit changed and we observed a reversal when the driver of
outcome was high-dose dependent while the NTCP model was mean-dose dependent.
By converting trial results into probability distributions, we demonstrated large
heterogeneity in predicted benefit, and provided a randomized measure of the precision
of individual benefit estimates.
Conclusions: The design allows for quantifying the benefit of PrT referral, based on the
combination of NTCP models, clinical risk factors, and traditional randomization. A
misspecified model can be detected through a lower-than-expected hazard ratio per
predicted DNTCP.
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Introduction
Radiation oncology has—as have many other technology-driven medical disciplines—struggled to generate level I evidence
demonstrating the clinical benefits of technologic advances. This is also the case for proton therapy [1], where the superiority
over standard photon therapy remains controversial [2–4], even for widely accepted treatments such as pediatric malignancies
[5–7]. It has been suggested that purely relying on evidence created from randomized controlled trials (RCTs) may not be the
optimal way of identifying patients (or patient groups) likely to benefit from proton therapy [8–11]. An alternative methodology
for development of data-based treatment strategies involves prediction of individual patient benefit using normal tissue
complication probability (NTCP) models [8]. The health care payers in some European countries have accepted NTCP model
predictions as a basis for reimbursement of the cost of proton therapy [8, 12]. Still, selection of patients, based on outcome
prediction models, suffers from risk of bias or inaccurate results if the underlying model lacks in accuracy or generalizability.
From an evidence-based medicine perspective, proton and photon therapies should be compared in RCTs, as would be
required for any novel drug, except in indications where the benefit is deemed to be so large that randomization as a method
for avoiding bias may not be necessary [13, 14]. At the time of writing, a number of clinical trials of proton therapy are indeed in
progress in a wide range of indications [15]. The challenge of this approach is that simple head-to-head comparison ignores
the expected heterogeneity of treatment effect: Some patients may expect large benefits from proton therapy in terms of
toxicity reduction, while others may have relatively little to gain (or might even be disadvantaged). Or to put it differently: an
RCT of proton versus photon therapy may provide a methodologically correct answer to the wrong question—whether protons
are uniformly better than photons in a defined population of patients—while missing out on the more relevant question—who, if
any, among the patients will have a clinically meaningful benefit from proton therapy compared with photon therapy.
Here, we propose and simulate an approach where the heterogeneous treatment benefit of proton therapy predicted by a
model is incorporated into the trial design. This idea also extends into the recurrent discussions regarding personalized
medicine [16], where technology-driven improvements have the potential to play a major role. We show how such a
randomized trial may provide a randomized estimate of the patient-level benefit from proton therapy, using comparative dose
planning and taking clinical risk factors for toxicity into account.
As a proof-of-concept, we demonstrate the design and interpretation of a hypothetical trial of definitive radiation therapy for
locally advanced non–small cell lung cancer (NSCLC), with radiation-induced pneumonitis (RP) as the primary endpoint. The
model used at point of analysis of the trials is an individualized QUANTEC (iQUANTEC) model taking clinical risk factors into
account [17, 18].
Materials and Methods
Dose Planning
Twenty consecutive patients with locally advanced NSCLC treated with definitive radiation therapy and concomitant
chemotherapy at our center, from January 1, 2015, and onwards, were selected as dose-planning cases, to provide realistic
estimates of interpatient heterogeneity in dose metric differences. This retrospective study was approved by the Danish Health
Authority, approval No. 3-3013-817/1, in accordance with Danish law. All patients were treated in free breathing with
volumetric modulated arc therapy. Robust proton dose plans were generated, and clinical photon plans and generated proton
dose plans fulfilled clinical constraints. See Supplementary Materials for additional information on patient data, dose planning,
and clinical constraints.
Dose-Volume Histogram Data
For each dose plan (photon and proton) the mean lung dose (MLD) and the volumes receiving at least 10 Gy, 20 Gy, 30 Gy, 40
Gy, and 60 Gy (V10Gy, V20Gy, V30Gy, V40Gy, and V60Gy) were retrieved for the lungs (total lung minus gross tumor volume).
Mean heart dose and V35Gy to esophagus were also retrieved. Data were retrieved with Eclipse Scripting API (version 13.6)
using in-house developed software (Visual Studio Community Edition 2015).
We considered the setting of a randomized trial of proton versus photon therapy for locally advanced NSCLC, with rate of
symptomatic RP as primary endpoint and with a 1:1 allocation ratio to the 2 trial arms and 300 patients per arm. Figure 1
shows the overall simulation setup.
We assumed the risk of RP could be predicted by the dose plan MLD and calculated an individual patient risk factor,
NTCPsum, for RP, using an individualized QUANTEC model (iQUANTEC) [18]. This model uses the dose-response
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relationship for symptomatic RP found in the QUANTEC review [19], but integrates additional clinical risk factors identified in a
literature-based meta-analysis and their associated odds ratios (ORs) [20] (see Figure 2). We assumed a logistic dose-
response relationship and estimated the OR for RP compared to a reference (see below) for a patient with a specific MLD and
a set of clinical risk factors X1, X2..., as
OR ¼ e4 c50D50MLDOR1OR2 . . .ORð...Þ:ð1Þ
A summarized individual patient risk was estimated by using the logarithm of the OR, NTCPsum ¼ ln(OR), as this is additive
in changes in risk factors.
We simulated outcomes by using a Weibull hazard function, h(t), parameterized by the shape and scale parameters q and
k:
hðtÞ ¼ kqtq1:ð2Þ
Individual changes in the estimated risk of event (RP) were modeled by adjusting the scale parameter
krisk ¼ kexp(NTCPsum) ¼ kOR. Further, we required a patient with baseline clinical risk factors and average MLD with photon
therapy (17.0 Gy) to have a probability of freedom from RP at 2 years of 85%, which in turn defines q ¼ 0.6 and k ¼ 0.11.
Finally, we assumed follow-up evenly distributed over a 2-year period.
For simulation of trial outcomes, we used bootstrap resampling from the 20 patients with dual planning. For each sample,
we used the photon dose plan MLD for risk estimation based on dose and randomly sampled clinical risk factors as identified
by Vogelius and Bentzen [20], with prevalences as summarized in the study of Appelt et al [18]: preexisting pulmonary
comorbidity, OR 2.27, prevalence 0.26; mid or inferior tumor location, OR 1.87, prevalence 0.44; current smoker, OR 0.62,
prevalence 0.28; age .63 years, OR 1.66, prevalence 0.50.
To include the effect of the experimental treatment (proton therapy), we calculated the individual change in risk (ie, DNTCP)
resulting only from the reduction in NTCP by using the difference in MLD between photon and proton therapy. We randomly
selected patients for the experimental arm and adjusted their individual risk factor according to: NTCPsum.proton ¼
NTCPsum.photon þ DNTCP. Event times were simulated by sampling from the corresponding Weibull distribution (ie, with krisk,
Figure 1. Schematics of the trial simulation setup. Twenty patients
with dual planning provided a distribution of dose plans. These dose
plans were input into a simulation model, which used either the
iQUANTEC/QUANTEC model based on mean lung dose or a VXX
model to simulate a baseline risk of toxicity corresponding to a given
dose distribution. These data were forwarded to a simulation stage,
where the dose plans were sampled with replacement for up to 2
3 300 simulated trial patients. Each patient also had a randomly
generated set of clinical risk factors (smoking, pulmonary
comorbidity, and age), and the combination of the radiation dose and
clinical risk factors could then be used to generate a patient-specific
Weibull distribution of event probability versus follow-up time.
Simulated binary survival data were generated from the
corresponding probabilities. The result was a 2 3 300 patient data
structure simulating clinical outcomes in a trial. This ‘‘in silico trial
dataset’’ was analyzed according to our suggested strategy: using
the complication probability of an individualized QUANTEC NTCP
model as a covariate in a Cox model (see figure for the exact
expression used in the model). Abbreviations: HR, hazard ratio; MLD,
mean lung dose; NTCP, normal tissue complication probability.
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based on either NTCPsum.proton or NTCPsum.photon, as appropriate), and censoring times were randomly sampled from a
uniform distribution over the interval of 0 to 2 years.
Once the simulated trial dataset was created, we used the Cox proportional hazards model to analyze the data. The DNTCP
and NTCPsum.photons were always included as covariates in the Cox model (Figure 1).
Model Misspecification
Model misspecification refers to the scenario where the user is making NTCP and DNTCP estimates (eg, in the model-based
selection process) based on a certain parametrization (eg, MLD), but where the driver of toxicity is another metric (eg, lung
V40Gy).
To study the effect of model misspecification, we changed the dose-volume model used in the simulation of outcome data
while keeping the analysis of trial data the same. The assumed alternative driver dose-response models were based on dose
cutoffs (VXX-driven models) and were taken from literature data [21]. These models did not account for clinical risk factors and
were not modified further. Fitting a logistic model to the data set provided estimates of c50 and D50 (See Supplementary
Materials). As Willner et al [21] only included predictive parameters up to V40Gy, the data were extrapolated to V60Gy in order to
test a dose metric that correlated differently with MLD in the photon and proton plans (Figure 3). Supplementary Materials
tabulate c50 and D50 estimates for the different models; see Figure 2 for graphical versions of all models.
For both the main analysis (Trial Simulation) and the model misspecification we simulated 1000 trials each with 23 300
patients and report the resulting estimate of the logarithm of the hazard ratio [log(HR)] per DNTCP from the Cox model.
Log(HR) per DNTCP is calculated by assuming the QUANTEC model for MLD (receiver model) regardless of which model was
used to drive the simulated trial outcomes. To assess the effect of uncertainty associated with delivery of proton therapy on the
trial outcome, we also included a worst-case proton plan MLD, selected from the uncertainty calculations performed during the
planning process (using uncertainties of 0.5-cm isocenter shift and 3.5% calibration curve error). The worst-case proton plan
was defined as the uncertainty plan with the highest MLD and was used as alternative driver dose-response models.
Application of Trial Results in Selecting Patients for Referral
Finally, we wanted to illustrate how the outcome of a trial could be used to support clinical decisions for future patients. The
most frequent log(HR) per DNTCP, from 1000 simulations with a correctly specified model, was used for illustration. The trial
yielded a log(HR) per DNTCP (based on a randomized comparison) for protons versus photons and we converted this result
into an estimate of the expected benefit in 4 illustrative cases: the patient with the highest DMLD and a patient with
approximately median DMLD, in both cases assuming no clinical risk factors or all clinical risk factors present (note that
‘‘current smoker’’ has a protective effect, ie, OR , 1). The effect size estimate of the Cox proportional hazards model could be
Figure 2. MLD dose-risk
models (left) from Marks et al
[19] and Appelt et al [18].
Alternative dose-risk models
(right) for the dose-volume
histogram parameters used in
simulation of outcomes (first
dark grey box in Figure 1) from
Willner et al [21]. Abbreviation:
MLD, mean lung dose.
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used to provide a probability distribution of absolute benefit from proton therapy at the individual patient level, using the basic
properties of the Cox model: NTCPsum:protons ¼ NTCPsum:photonsHR, where HR¼ exp(b*DNTCP) and b [¼log(HR)] were assumed
normally distributed according to the confidence interval of the simulated trial. This approach naturally combines the model
prediction (NTCP) and the result of randomization, as log(HR) is an estimate with DNTCP as covariable in strict randomization.
All simulations and analysis of outcome data were performed in RStudio (RStudio: Integrated Development for R, RStudio
Team [2015], RStudio Inc, Boston, Massachusetts).
Results
Dose Plan Comparison
The mean DMLD was 4.3 Gy when comparing the robust planned proton dose plans with the clinical photon dose plans
(Figure 3). The proton dose plans had a lower MLD and a lower V20Gy for all patients. However, V40Gy and V60Gy were higher
with protons in an increasing proportion of cases. Evaluating the worst-case proton plans, the mean DMLD was 3.2 Gy.
Trial Simulation
The simulated trials favored proton therapy when an input MLD-based model was used (correctly specified model), and
progressively decreased the predicted benefit of protons when the input model was changed from V10Gy towards V60Gy
(Figure 4). Assuming the worst-case MLD (MLD-robustness in Figure 4) from the proton uncertainty plans had a limited effect
on the trial outcome.
Figure 3. Dosimetric
comparison of the 20 patients’
photon (x-axis) and proton (y-
axis) doses to the lung
structure (lungs minus gross
tumor volume). The identity
line indicates where the 2
modalities yielded same
results, and points below the
identity line indicate superiority
of protons as compared to
photons and vice versa. Note
the different scales on both the
x- and y-axis.
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Use in Future Patients
We finally assumed the completion of a trial with a resulting estimate of the value of log(HR) for DNTCP. If the model was well
specified, the most frequent trial result was used: log(HR) per DNTCP ¼7.77 (95% confidence limit: 16.6 to 1.05). This
result was converted into probability distributions of predicted benefit, shown for 4 illustrative cases in Figure 5, detailing how a
patient with all risk factors in combination with a large DMLD reduction, comparing photons to protons, will have a reduced
probability of developing RP, namely, from 49% to 9%. Additionally, a patient with the same number of risk factors, but median
DMLD between the 2 modalities, will only have a 31% to 15% probability reduction.
Discussion
Our trial simulation incorporates heterogeneity of treatment effect and quantified risk at the individual patient level into a
randomized comparison of 2 treatment strategies. The aim is to obtain an unbiased estimation of how a difference in model-
predicted DNTCP converts into a clinical outcome on the patient level.
Figure 5 shows how outcomes from randomized trial results can be used to quantify the individual benefits of proton versus
photon therapy and thereby support the decision to refer to proton therapy on a rational basis. This allows moving from simple
Figure 4. Simulations of 1000
trials for each volumetric
parameter, according to the
scheme in Figure 1 for 2
3 300 patients. In the top set,
the model is correctly specified
(MLD used for simulating
outcome and MLD used in Cox
regression analysis of results).
On the x-axis is log(HR) per
DNTCP of the Cox proportional
hazards model. As expected,
when the MLD model is used
to generate data, the
outcomes favor the model-
predicted DNTCP
[log(HR) , 0]. When the
model is misspecified, the
outcome favors protons even
more for V10Gy as the
underlying model, and
progressively moves towards
favoring photons for the V60Gy
model as input (ie, HR per
DNTCP favors the plan with
highest NTCP in the model).
Comparing with Figure 3, this
illustrates that the trials will
reject a benefit of treating with
protons if V60Gy is the
underlying driver of RP, as
desired. *MLDþrobustness
assumes the worst MLD taken
from proton uncertainty plans,
using uncertainties of 0.5-cm
isocenter shift and 3.5%
calibration curve error.
Abbreviations: DVH, dose-
volume histogram; HR, hazard
ratio; MLD, mean lung dose;
NTCP, normal tissue
complication probability; RP,
radiation-induced pneumonitis.
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hypothesis testing in a comparative effectiveness trial towards individualized estimates of benefit. Arguably, the cases
presented in Figure 5 reflect subjective decisions already made by treating physicians, but the estimate of the HR per DNTCP
quantifies the relative merits of the 2 radiation modalities and provides decision support for patients, caregivers, and policy
makers. A supportive decision-making tool based on the data from this article has been developed in RStudio and is available
online at: https://protontrialsimulation.shinyapps.io/trial_webb/.
The trial design presented here still requires strict randomization. A possible elaboration on the present approach could be
to use adaptive Bayesian designs. In such a design patients with a large predicted benefit are randomly assigned with higher
weighting to proton therapy and when a predefined limit on the magnitude of benefit is exceeded, the patient can be allocated
to the according arm without randomization at all.
A major strength of the presented design is that future selection of patients does not rely on the model being correctly
specified. The estimate of HR per DNTCP adjusts the predicted benefit to the actual clinical data and thus reduces the risk of
wrongly allocating future patients to protons if, for example, the V60Gy model would be a better predictor of NTCP. In other
words, where the model-based approach relies on nonrandomized follow-up studies after implementation to identify model
misspecification, the current proposal detects model misspecification from randomized data through the HR per DNTCP from a
trial. Another strength of the design is that an uncertainty in the MLD did not affect the trial outcome (Figure 4).
It should be acknowledged that it is not ideal only to consider NTCP of a single endpoint in benefit estimations. Here we
focused on a single endpoint for simplicity, but further studies should look at several NTCP endpoints, preferably at a more
comprehensive NTCP profile as pointed out by others [11], but also include verification that the tumor control probability is not
affected by choice of modality.
Figure 5. Application of
hypothetical trial outcome for a
future patient. Top row: A
patient with photon MLD
¼ 18.9 Gy and proton MLD
¼ 11.0 Gy (highest DMLD
among the 20 patients). Top
left shows the case where this
patient has all risk factors (ie, a
patient with preexisting
pulmonary comorbidity, mid or
inferior tumor location, old age,
and not a current smoker)
present (50% chance of
improving NTCP from 48.6%
to less than 9.2%); and top
right shows the case where no
risk factors (no comorbidities,
upper tumor location, young
age, and current smoker) are
present (50% chance of
improving from 5.0% to 3.9%).
Bottom row: A patient with
photon MLD ¼ 13.6 Gy and
proton MLD ¼ 9.5 Gy (median
DMLD among the 20 patients).
Bottom left shows the case
where this patient has all risk
factors present and bottom
right shows the case where no
risk factors are present.
Abbreviations: MLD, mean
lung dose; NTCP, normal
tissue complication probability;
Proton exp, proton
experimental arm.
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To illustrate this point in the lung cancer radiation therapy setting, we considered acute esophagitis and heart complications,
both of which are of high relevance. We provide NTCP estimates for acute esophagus [22] and heart toxicity [23] in the
Supplementary Materials. A reduction in NTCP for the heart when using protons compared to photons was observed, but we
did not see a reduction in the risk of acute esophagitis (Supplementary Materials).
Evaluating only a reduction in MLD, the expected difference in RP in an RCT should favor intensity-modulated proton
therapy. A recent study from MD Anderson Cancer Center (Houston, Texas) on an RCT comparing modulated photon therapy
and passive scattering proton therapy in lung cancer [4] indicated that there was no difference in either MLD or RP rates
between the 2 arms. However, the authors noted a difference in RP between early and late inclusion in the proton group, with
no difference in MLD. The fact that the late proton group had both a significant smaller tumor volume and lower delivered dose
might explain the lower RP rate. This suggests that higher prescribed doses further elucidate the risk of a higher-than expected
dose metric from the lung and might itself be associated with the probability of RP induction when using proton therapy.
Conclusion
Our proposed trial design quantifies the benefit of referral to proton therapy, based on the combination of NTCP models and
traditional randomization. The proposed method behaves well under the investigated types of NTCP model misspecification
and provides quantitative benefit estimates on the individual patient level, which may have greater clinical utility than the
information derived from a traditionally designed RCT.
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